Know Cancer

forgot password

Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug

Phase 2
18 Years
60 Years
Not Enrolling
Metastatic Renal Cell Carcinoma

Thank you

Trial Information

Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug

Inclusion Criteria:

1. The patient must provide written informed consent prior to receiving Sorafenib.

2. The male or female patient must be at least 18 years of age.

3. The patient must have pathologically proven advanced Renal Cell Carcinoma.

4. Only patients with measurable disease (According to RECIST) at baseline should be
included in protocol where Disease Control Rate (DCR) is the primary endpoint.

5. The patient requires Sorafenib as First line therapy as the patient is unsuitable for
another approved first line therapy for advanced RCC.

6. The patient must be, in the Investigator's opinion, reasonably likely to benefit from
treatment with Sorafenib as a single agent.

7. The patient must have an Eastern Cooperative Oncology Group performance status of 0 -

8. The patient will not require other systemic anti-cancer chemotherapy, immunotherapy
or hormonal therapy, except for bisphosphonates while taking Sorafenib.

9. Both male and female patients must use adequate barrier birth control methods during
their participation in the protocol. The birth control methods must be used for 4
weeks for female patients and for 3 months for male patients after discontinuation of
treatment with Sorafenib.

10. For patients, who have had major surgery, the wound must be completely healed prior
to receiving Sorafenib treatment (4 weeks).

11. The patient must have within normal Renal & Hepatic function.

12. The patient must have within normal CBC.

Exclusion Criteria:

1. Patients who are currently enrolled in or have previously participated in any other
Sorafenib trial.

2. Suitable or received any other systemic therapy for treatment RCC (IL-2, INF)

3. Patients who have a life expectancy of less than 2 months.

4. Patients with metastatic brain or meningeal tumours.

5. Patients are excluded who require any of the following:

- Investigational drug therapy during the treatment with Sorafenib or within 30
days prior to their first dose of Sorafenib.

- Concomitant Rifampicin.

6. Non-measurable disease according to RECIST.

7. Concomitant St. John's Wort (Hypericum perforatum).

8. Warfarin (or similar medication) is allowed.

9. Women who are pregnant or breast-feeding. Women of childbearing potential must have a
negative pregnancy test performed within seven days of the start of study drug
(please note that no laboratory data are collected in this study).

10. Patients with congestive heart failure greater than NYHA functional class II
(symptomatic during ordinary activity)

11. Patients with cardiac arrhythmias greater than Grade 1 NCI CTCAE, Version 3.0
(conduction abnormality and supraventricular arrhythmia present but patient is
asymptomatic; intervention not indicated, palpitations present and QTc > 0.45 - 0.47

12. Patients with active coronary artery disease or ischemia.

13. Patients with Child-Pugh class C hepatic impairment.

14. Patients with severe renal impairment (calculated creatinine clearance of < 30
ml/min) or who require dialysis.

15. Patients with active uncontrolled hypertension.

16. Patients with recent or active bleeding diathesis.

17. Patients with any medical condition which could jeopardize their safety while taking
an investigational drug.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

evaluate the efficacy by evaluating the disease control rate (DCR) and safety of Sorafenib for first line patients unsuitable for another approved first line therapy with advanced RCC in the Middle East region.

Outcome Time Frame:

Disease Control Rate (DCR) defined as either CR, PR or SD for at least 8 weeks

Safety Issue:


Principal Investigator

Hussein M. Khaled, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Egyptian Foundation For Cancer Research


Egypt: Institutional Review Board

Study ID:




Start Date:

October 2008

Completion Date:

March 2010

Related Keywords:

  • Metastatic Renal Cell Carcinoma
  • Carcinoma
  • Carcinoma, Renal Cell